The short answer
A specific goldenseal root-capsule product reduced metformin exposure in healthy volunteers, but that does not establish the same effect for every goldenseal extract. The preparation’s composition matters, and reduced exposure has not consistently translated into worse glucose control. Have the exact extract reviewed before combining it with metformin.
What this answer covers
Hydrastis canadensis extract node: human evidence comes from a characterized product described both as root-extract capsules and dried root material. Whole-root follow-up evidence is indirect to an unspecified extract.
- Supplement or preparation
- Hydrastis Canadensis (Goldenseal) Extract
- Medication ingredient
- metformin
Which extract was tested?
The earlier study describes a Now Foods product as 500 mg root-extract capsules, while also characterizing it as dried Hydrastis root material. Investigators separately made a methanol extract for laboratory tests; that laboratory extract was not what volunteers swallowed. This distinction matters when comparing a commercial concentrated extract, tincture or isolated berberine product.
How large was the measured effect?
Sixteen healthy adults took a metformin solution containing 50 mg after several days of the characterized goldenseal product. Total metformin exposure fell about 23% and its peak about 27%, without a change in kidney clearance. These findings establish an effect for that tested combination, not a universal percentage reduction in absorption or a measured rate of diabetes treatment failure.
Does the newer patient study settle the question?
The 2025 patient study used a different, explicitly whole-root product. It found no meaningful aggregate exposure change, with larger changes in lower-dose and immediate-release subgroups. HbA1c did not worsen on average. Because the preparation and population differed, this study is useful context but cannot certify an unspecified extract as equivalent or safe.
What information should I bring?
Bring the species, plant part, extraction ratio, solvent if listed, alkaloid standardization and full ingredient panel. Also identify whether your metformin is immediate or extended release. No studied gap guarantees that an extract will not affect treatment. Agree on a plan with your clinician rather than changing metformin to compensate for a predicted percentage.
Evidence and practical considerations
Absorption & effectiveness
A specific goldenseal root-capsule product reduced metformin exposure in healthy volunteers, but that does not establish the same effect for every goldenseal extract. The preparation’s composition matters, and reduced exposure has not consistently translated into worse glucose control. Have the exact extract reviewed before combining it with metformin.
- Exact scope
- specific chemically characterized goldenseal root-capsule product; other extract ratios/solvents and isolated berberine not established equivalent with oral metformin; hydrochloride IR, ER or low-dose solution retained source by source
- Medication form and route
- oral
- Timing or duration
- Five-day root-product exposure with a subtherapeutic metformin probe; indirect acute/28-day whole-root follow-up.
What remains uncertain
- The broad extract node lacks extraction ratio and composition. Preserve preparation uncertainty and do not assign every extract the study percentage.
Factors that may matter: exact preparation and dose; medication formulation and duration; other medicines and underlying conditions; source population and measured outcome.
Read the supporting source summaries
Source 1: regulatory product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Adults receiving oral extended-release metformin hydrochloride.
Advises annual hematologic assessment and B12 measurements every 2-3 years. Hypoglycemia is uncommon with metformin alone but risk is greater with insulin or secretagogues and other circumstances.
How this applies: Exact metformin parent RxCUI 6809 with hydrochloride formulation retained. Monitoring and general precautions only unless B12 is the counterparty. Counterparty scope for this package: specific chemically characterized goldenseal root-capsule product; other extract ratios/solvents and isolated berberine not established equivalent.
Extended-release label is not a study of immediate-release interaction kinetics; no aloe, chromium or goldenseal-specific effect or interval quantified.
Source 2: original human pharmacokinetic study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 16 healthy adults, 8 men and 8 women, completed open-label fixed-sequence crossover.
Metformin AUC fell 23% and peak 27%; half-life and renal clearance unchanged. No glucose efficacy endpoint at this subtherapeutic metformin dose.
How this applies: Exact metformin and characterized Hydrastis root product. Preserve the authors’ dual root-extract/dried-root descriptions; do not infer generic extract equivalence. Counterparty scope for this package: specific chemically characterized goldenseal root-capsule product; other extract ratios/solvents and isolated berberine not established equivalent.
One characterized product and healthy volunteers; laboratory methanol extract prepared separately and not the consumed product. No proof for every extraction process or for clinical treatment failure.
Source 3: original human pharmacokinetic crossover study
pmc.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 22 adults with type 2 diabetes, 12 men and 10 women; immediate-release or extended-release metformin.
Aggregate AUC ratio 0.93 (90% CI 0.86-1.01) met no-effect criterion. Larger exposure reductions at lower doses and immediate release; no mean high-dose reduction. HbA1c fell 6.8% to 6.5% in 15 evaluable participants; other glucose markers did not corroborate improvement.
How this applies: Direct whole-root/metformin study. It limits claims that lower measured exposure inevitably worsens diabetes control; extraction-node use is indirect. Counterparty scope for this package: specific chemically characterized goldenseal root-capsule product; other extract ratios/solvents and isolated berberine not established equivalent.
Small nonrandomized dose/formulation groups; fixed last chronic arm, participation bias and no power for clinical glycemic outcomes. Whole root, not interchangeable with all extracts.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Original evidence and current labels checked; complete private article and exact-current-claim adjudications prepared. | |
| Research summary published |
Article revision: 3ae20872172307a8
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.